JP5539216B2 - 非ヌクレオシド系逆転写酵素阻害剤 - Google Patents

非ヌクレオシド系逆転写酵素阻害剤 Download PDF

Info

Publication number
JP5539216B2
JP5539216B2 JP2010534947A JP2010534947A JP5539216B2 JP 5539216 B2 JP5539216 B2 JP 5539216B2 JP 2010534947 A JP2010534947 A JP 2010534947A JP 2010534947 A JP2010534947 A JP 2010534947A JP 5539216 B2 JP5539216 B2 JP 5539216B2
Authority
JP
Japan
Prior art keywords
chloro
pyridin
pyrazolo
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010534947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503230A5 (enExample
JP2011503230A (ja
Inventor
タツカー，トーマス・ジエイ
テイネボア，ロバート
シスコ，ジヨン・テイー
アンソニー，ネビル
ゴメス，ロバート
ジヨリー，サムソン・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2011503230A publication Critical patent/JP2011503230A/ja
Publication of JP2011503230A5 publication Critical patent/JP2011503230A5/ja
Application granted granted Critical
Publication of JP5539216B2 publication Critical patent/JP5539216B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010534947A 2007-11-20 2008-11-14 非ヌクレオシド系逆転写酵素阻害剤 Expired - Fee Related JP5539216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US376907P 2007-11-20 2007-11-20
US61/003,769 2007-11-20
PCT/US2008/012774 WO2009067166A2 (en) 2007-11-20 2008-11-14 Non-nucleoside reverse transcriptase inhibitors

Publications (3)

Publication Number Publication Date
JP2011503230A JP2011503230A (ja) 2011-01-27
JP2011503230A5 JP2011503230A5 (enExample) 2012-01-05
JP5539216B2 true JP5539216B2 (ja) 2014-07-02

Family

ID=40336474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534947A Expired - Fee Related JP5539216B2 (ja) 2007-11-20 2008-11-14 非ヌクレオシド系逆転写酵素阻害剤

Country Status (12)

Country Link
US (1) US8404856B2 (enExample)
EP (1) EP2222661B1 (enExample)
JP (1) JP5539216B2 (enExample)
KR (1) KR20100088142A (enExample)
CN (1) CN101952274A (enExample)
AU (1) AU2008326784B2 (enExample)
BR (1) BRPI0820162A2 (enExample)
CA (1) CA2705834A1 (enExample)
IL (1) IL205386A0 (enExample)
MX (1) MX2010005483A (enExample)
RU (1) RU2010125220A (enExample)
WO (1) WO2009067166A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010026075A1 (en) * 2008-09-04 2010-03-11 F. Hoffmann-La Roche Ag Pyridine derivatives as inhibitors of hiv-i reverse transcriptase
WO2011049987A2 (en) * 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
US8486975B2 (en) 2010-03-30 2013-07-16 Merck Canada Inc. Non-nucleoside reverse transcriptase inhibitors
WO2011126969A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor
US9150539B2 (en) * 2012-09-26 2015-10-06 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2928472B1 (en) * 2012-12-05 2018-05-02 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
ES2759976T3 (es) * 2013-12-04 2020-05-12 Merck Sharp & Dohme Proceso para fabricar inhibidores de la transcriptasa inversa
RU2693622C2 (ru) 2014-04-01 2019-07-03 Мерк Шарп И Доум Корп. Пролекарственные средства ингибиторов обратной транскриптазы вич
ES2886641T3 (es) 2014-08-11 2021-12-20 Angion Biomedica Corp Inhibidores de citocromo P450 y sus usos
EP3240778A4 (en) 2014-12-31 2018-07-11 Angion Biomedica Corp. Methods and agents for treating disease
CA2998646C (en) * 2015-09-23 2021-05-18 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
SG11201804098TA (en) 2015-11-20 2018-06-28 Forma Therapeutics Inc Purinones as ubiquitin-specific protease 1 inhibitors
US10981916B2 (en) 2016-12-28 2021-04-20 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
EP3717488B1 (en) 2017-11-27 2021-09-29 Dart NeuroScience, LLC Substituted furanopyrimidine compounds as pde1 inhibitors
PH12021551408A1 (en) 2018-12-18 2022-05-16 Merck Sharp & Dohme Llc Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
CN114026081B (zh) * 2019-05-22 2025-02-11 默沙东有限责任公司 作为针对hiv感染的细胞的选择性细胞毒性剂的吡啶酮衍生物
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CN112876409A (zh) * 2021-01-20 2021-06-01 都创(上海)医药科技股份有限公司 一种2-(5-溴-6-甲氧基吡啶-2-基)乙腈及其衍生物的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) * 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
CA2160928C (en) * 1993-07-28 2005-07-05 Garry Fenton Compounds as pde iv and tnf inhibitors
AU4137899A (en) * 1998-04-27 1999-11-16 Centre National De La Recherche Scientifique 3-(amino-or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
AU2001234420A1 (en) * 2000-02-03 2001-08-14 Eli Lilly And Company Potentiators of glutamate receptors
WO2002022604A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002024650A2 (en) * 2000-09-19 2002-03-28 Centre National De La Recherche Scientifique (Cnrs) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
CA2476012C (en) * 2002-02-14 2011-04-19 Pharmacia Corporation Substituted pyridinones as modulators of p38 map kinase
JP5602333B2 (ja) 2003-02-07 2014-10-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ感染の予防のためのピリミジン誘導体
WO2004085406A1 (en) * 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
US20050014774A1 (en) * 2003-04-28 2005-01-20 Richard Storer Oxo-pyrimidine compounds
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
EP1742908B1 (en) 2004-04-23 2009-11-11 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
TWI360539B (en) * 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
CA2592092A1 (en) * 2004-12-22 2006-06-29 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009515826A (ja) * 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
RU2008119412A (ru) 2005-10-19 2009-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) N-фенил-фенилацетамидные ненуклеозидные ингибиторы обратной транскриптазы
US8778977B2 (en) * 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
WO2008098143A2 (en) * 2007-02-08 2008-08-14 Trius Therapeutics Antimicrobial compounds and methods of use

Also Published As

Publication number Publication date
RU2010125220A (ru) 2011-12-27
EP2222661B1 (en) 2016-04-20
CA2705834A1 (en) 2009-05-28
EP2222661A2 (en) 2010-09-01
US20100256181A1 (en) 2010-10-07
US8404856B2 (en) 2013-03-26
KR20100088142A (ko) 2010-08-06
WO2009067166A3 (en) 2009-07-16
MX2010005483A (es) 2010-06-11
BRPI0820162A2 (pt) 2019-09-24
IL205386A0 (en) 2010-12-30
JP2011503230A (ja) 2011-01-27
AU2008326784B2 (en) 2014-04-24
WO2009067166A2 (en) 2009-05-28
CN101952274A (zh) 2011-01-19
AU2008326784A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
JP5539216B2 (ja) 非ヌクレオシド系逆転写酵素阻害剤
AU2020257055B2 (en) Cot modulators and methods of use thereof
JP7789662B2 (ja) Ｍｔａ協働ｐｒｍｔ５阻害剤
JP6982343B2 (ja) 治療用阻害化合物
JP5123949B2 (ja) 非ヌクレオシド逆転写酵素阻害剤
AU2015335694B2 (en) Indole carboxamide compounds useful as kinase inhibitors
CN102099036B (zh) 用于治疗炎性疾患和纤维化疾患的化合物和方法
CN104822267B (zh) 乙型肝炎病毒共价闭合环状dna形成的抑制剂及其使用方法
TWI535442B (zh) A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
TW202140441A (zh) 經取代之側氧基異吲哚啉化合物
KR20140071384A (ko) C-kit 키나제 억제제로서의 화합물 및 조성물
TW201018684A (en) New compounds
KR20140071383A (ko) C-kit 키나제 억제제로서의 화합물 및 조성물
AU2012250059A1 (en) Aldosterone synthase inhibitors
BG99879A (bg) Инхибитори на нiv реверсивна транскриптаза
ES2468221T3 (es) Derivados de bencimidazol y composiciones farmacéuticas del mismo
EP1928455A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
CN114981256B (zh) 干扰素基因刺激物sting的单环激动剂
WO2019000504A1 (zh) 5型磷酸二酯酶抑制剂及其制备方法和用途
EP3087074A1 (en) Benzene sulfonamides as ccr9 inhibitors
TW202412773A (zh) 雜芳基衍生化合物及其用途
WO2002081446A1 (en) 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof
KR100552925B1 (ko) 3-사이클로펜틸옥시-4-메톡시페닐-이소인돌리논 유도체 및그의 용도
EA048870B1 (ru) Замещенные оксоизоиндолины
NZ621092B2 (en) COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111111

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120629

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20120808

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140408

R150 Certificate of patent or registration of utility model

Ref document number: 5539216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140430

LAPS Cancellation because of no payment of annual fees